mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
Elena Azzolini, Chiara Pozzi, Luca Germagnoli, Bianca Oresta, Nicola Carriglio, Mariella Calleri, Carlo Selmi, Maria De Santis, Silvia Finazzi, Carmelo Carlo‐Stella, Alexia Bertuzzi, Francesca Motta, Angela Ceribelli, Alberto Mantovani, Fabrizio Bonelli, María Rescigno
Abstract
SARS-CoV-2 vaccination has proven effective in inducing an immune response in healthy individuals and is progressively us allowing to overcome the pandemic. Recent evidence has shown that response to vaccination in some vulnerable patients may be diminished, and it has been proposed a booster dose. We tested the kinetic of development of serum antibodies to the SARS-CoV-2 Spike protein, their neutralizing capacity, the CD4 and CD8 IFN-γ T-cell response in 328 subjects, including 131 immunocompromised individuals (cancer, rheumatologic, and hemodialysis patients), 160 health-care workers (HCW) and 37 subjects older than 75 yr, after vaccination with two or three doses of mRNA vaccines. We stratified the patients according to the type of treatment. We found that immunocompromised patients, depending on the type of treatment, poorly respond to SARS-CoV-2 mRNA vaccines. However, an additional booster dose of vaccine induced a good immune response in almost all of the patients except those receiving anti-CD20 antibody. Similarly to HCW, previously infected and vaccinated immunocompromised individuals demonstrate a stronger SARS-CoV-2-specific immune response than those who are vaccinated without prior infection.